<DOC>
	<DOCNO>NCT02139592</DOCNO>
	<brief_summary>The purpose study evaluate safety brentuximab vedotin ( recombinant ) IV infusion ( ADCETRIS IV Infusion 50 mg ) patient relapsed/refractory CD30+ Hodgkin 's lymphoma anaplastic large cell lymphoma routine clinical setting , well collect efficacy information reference .</brief_summary>
	<brief_title>Brentuximab Vedotin ( Recombinant ) IV Infusion - Special Drug Use Surveillance ( All-case Surveillance ) `` Relapsed Refractory CD30+ Hodgkin 's Lymphoma Anaplastic Large Cell Lymphoma ''</brief_title>
	<detailed_description>The present survey design evaluate safety brentuximab vedotin ( recombinant ) IV infusion ( ADCETRIS IV Infusion 50 mg ) patient relapsed/refractory CD30+ Hodgkin 's lymphoma anaplastic large cell lymphoma routine clinical setting . The usual adult dosage 1.8 mg/kg ( body weight ) brentuximab vedotin ( recombinant ) infuse intravenously every three week . The dose adjust depend patient 's condition . See `` PRECAUTIONS '' section package insert .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All patient treat ADCETRIS IV Infusion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>